NCT00537966 Characterization of Acute and Recent HIV-1 Infections in Zurich.
| NCT ID | NCT00537966 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Zurich |
| Condition | HIV Infections |
| Study Type | OBSERVATIONAL |
| Enrollment | 800 participants |
| Start Date | 2002-01 |
| Primary Completion | 2028-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 800 participants in total. It began in 2002-01 with a primary completion date of 2028-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Aim of the study: To study and to describe factors which could influence the course of primary HIV infection (PHI) and factors that in turn could be influenced through PHI. In summary, this study will provide comprehensive knowledge on early HIV-infection with regard to epidemiology, impact of early-cART on the course of disease and forms the base for a variety of translational research projects addressing early key pathogenesis events between virus and host, relevant for the course of disease, for transmission, for development of vaccines and new treatment strategies.
Eligibility Criteria
Inclusion Criteria: A) acute HIV-1 infection, defined as: * negative or evolving immunoblot in the presence of positive p24 Ag and/or detectable plasma HIV-1 RNA and/or * documented HIV seroconversion within 90 dayswith or with-out symptoms and/or clinical signs of PHI (e.g. acute retro-viral syndrome). B) recent HIV-1 infection, defined as: * documented seroconversion of more than 90 days but within 180 days and/or * evolving immunoblot after unambiguous transmission risk (e.g. iv drug use, sexual contact) within 180 days and/or * documented HIV infection and unambiguous transmission risk (iv drug use, sexual contact) within 180 days and/or * documented HIV infection and possible transmission risk (iv drug use, sexual contact) within the last 180 days after infection AND \< 0.5% fraction of ambiguous nucleotides Exclusion Criteria: • Documented HIV infection, however, established diagnosis more than 180 days after presumed date of infection.
Contact & Investigator
Huldrych. Günthard, MD
PRINCIPAL INVESTIGATOR
UniversitaetsSpital Zuerich
Frequently Asked Questions
Who can join the NCT00537966 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying HIV Infections. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00537966 currently recruiting?
Yes, NCT00537966 is actively recruiting participants. Contact the research team at Huldrych.Guenthard@usz.ch for enrollment information.
Where is the NCT00537966 trial being conducted?
This trial is being conducted at Zurich, Switzerland.
Who is sponsoring the NCT00537966 clinical trial?
NCT00537966 is sponsored by University of Zurich. The principal investigator is Huldrych. Günthard, MD at UniversitaetsSpital Zuerich. The trial plans to enroll 800 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.